ImmunityBio, Inc.

Glioblastoma is not only among the most common malignant brain tumors - it is also one of the most aggressive and difficult to treat. Advancing care requires new approaches. Learn more about how we are exploring the potential of the immune system to enhance how the body identifies and responds to cancers such as glioblastoma: immunitybio.com/glioblastoma/

At ImmunityBio, we continue to prioritize long-term growth and the advancement of our broader immunotherapy platform. This additional non-dilutive financing supports our effort to expand globally with the goal of improving outcomes for patients. Read more: immunitybio.com/immunitybio-st…

ImmunityBio confirmed statistical power in our pivotal randomized trial evaluating ANKTIVA® + BCG versus BCG alone in BCG-naïve NMIBC, supporting the ability to detect clinically meaningful differences between treatment arms. This milestone builds on prior interim findings showing improved durability of complete response with ANKTIVA + BCG, reinforcing continued evaluation in earlier disease settings. Learn more: immunitybio.com/immunitybio-co…

We believe the future of non-small cell lung cancer (NSCLC) treatment lies in novel strategies that more effectively harness the immune system. Learn more about how we're working to evolve treatment for patients living with this disease: immunitybio.com/immunitybio-an…

A step forward in global expansion: ANKTIVA® (nogapendekin alfa inbakicept-pmln) has received regulatory approval in Macau SAR, China for patients with BCG-unresponsive NMIBC ± CIS papillary tumors. Explore the full announcement: immunitybio.com/immunitybio-an…

According to the American Cancer Society's 2026 Facts & Figures, bladder cancer remains a significant burden for patients, underscoring the urgent need for more effective and patient-centered treatment options. At ImmunityBio, we're focused on reducing the burden of care while advancing meaningful solutions.

Progress in non-muscle invasive bladder cancer (NMIBC) care is driven by a deeper understanding of the disease and a commitment to improving treatment options for patients. Our work is focused on supporting advancements that may help redefine how NMIBC is managed.

The NCCN® Clinical Practice Guidelines now include ANKTIVA® plus BCG for patients with BCG-unresponsive NMIBC with papillary-only disease. This update reflects continued progress in expanding treatment considerations for patients facing limited options following BCG therapy. Learn more: immunitybio.com/immunitybio-an…

We're expanding our team with individuals who are ready to innovate, collaborate, and help bring next-generation therapies to patients. If you're looking to contribute to work with real purpose, learn more about the positions we're hiring for: immunitybio.com/careers/

We’ve announced a milestone in large-scale production and cryopreservation of memory cytokine-enhanced natural killer (NK) cells from more than 60 healthy and cancer donors, supporting ongoing research in NK cell–based therapies. Read more: immunitybio.com/immunitybio-ac…

This submission follows the FDA's review of additional data and represents an important regulatory step in expanding potential treatment options for adult patients with BCG-unresponsive NMIBC with papillary disease. Read more: immunitybio.com/immunitybio-an…

Dr. Patrick Soon-Shiong, Founder, Executive Chairman, and Global Chief Scientific & Medical Officer of ImmunityBio, joined @NewsNation’s Cuomo Special Edition to discuss the scientific and systemic challenges behind curing cancer as well as the path forward through innovation in immunotherapy. Watch the full conversation now on YouTube: youtu.be/L6gbF1kuHiQ

WATCH: New approaches to fighting cancer are shifting focus toward boosting the immune system. Dr. Patrick Soon-Shiong explains how AI-engineered antibodies could redefine treatment.

ImmunityBio will host a live conference call at 1:30 p.m. PT (4:30 p.m. ET) on Tuesday, March 3, 2026, to provide a business update, discuss progress across our clinical trial pipeline, and review financial results for the year ended December 31, 2025. Participants can join via our Investor Relations site or by phone; a replay will be available afterward. Learn more: ir.immunitybio.com/news-releases/…

ImmunityBio has completed enrollment in our pivotal randomized Phase 2 trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus BCG versus BCG alone in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. The FDA-requested interim analysis demonstrated a statistically significant improvement in duration of complete response, with no new safety concerns observed. A BLA submission is anticipated in Q4 2026. Read more: ir.immunitybio.com/news-releases/…

During his presentation at the “Cancer 2035: A Roadmap for the Future” Summit hosted by the @MilkenInstitute and the @nixonfoundation, Dr. Patrick Soon-Shiong discussed the central role of coordinated innate and adaptive immune activation in cancer therapy. By leveraging immunogenic cell death and restoring immune system function, emerging strategies aim to generate sustained, systemic anti-tumor responses. ImmunityBio is focused on developing therapies that work with the immune system, not around it.

At ImmunityBio, we're pioneering immunotherapies to transform the path of complex cancers, aiming to bring better, more meaningful outcomes for patients. Explore the science behind the future we're building: immunitybio.com/platforms/